Drugs / Plasma-derived FVIII/VWF concentrate
Plasma-derived FVIII/VWF concentrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02479087 | Jan 2015 → Jan 2019 | hemophilia A | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasma-derived FVIII/VWF concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02479087 ↗ |
| Modality | Protein / enzyme biologic | “The investigational treatment is with lyophilized plasma-derived Factor VIII.” NCT02479087 ↗ |
| Route | Intravenous | “The drug will be delivered through intravenous slow infusion/injection.” NCT02479087 ↗ |